



# Oxford Pharmascience [AIM:OXP]

*Medicines Made Better*

Company Introduction

Masters Investor Show 2016

23 April 2016

**Applying proprietary formulation technologies to approved drugs to make them better, safer and easier to take**

1. **EXPzero™** NSAIDs lead programme developing **improved formulations** of major NSAIDs<sup>(1)</sup>
  2. **Safestat™** programme aims to develop statin formulations with higher efficacy and improved tolerance, ideal for OTC switch
- **Focus is on previously approved drugs meaning:**
    - Reduced risk: simplified drug development regulatory pathway
    - Reduced cost
    - Faster access to market

# Next Generation NSAIDs Programme

## Significant opportunity

- Re-developing NSAIDs\* the most commonly used medicines: ibuprofen, naproxen and aspirin
- Range of benefits to differentiate and deliver competitive advantage
- Proprietary technology underpinned by strong IP

## Near term growth

- Pipeline addresses main molecules of the c.\$12bn NSAIDS market
- Multiple routes to market through partnerships in both OTC and Rx markets

## Deliverable outcome


- Commercialisation process started (OXZero™ Ibuprofen and OXZero™ Naproxen)
- Well funded to advance further clinical work if deemed appropriate

**Significant value opportunities for partners in OTC and Rx markets**

# The Market

- Multiple opportunities in over the counter (OTC) and prescription (Rx)
- OXP is selectively targeting the largest components of the massive c.\$12bn Global NSAIDs market, leading with “pain” molecules.

Global NSAIDs market (at Manufacturers' Selling Prices, \$bn)<sup>1</sup>



# The Problem

---

- Need for relevant product differentiation
  - Market share erosion from own label and generics
  - Pricing pressure from own label and generics
  - Well documented gastrointestinal (GI) safety issues with Ibuprofen/NSAIDs
  - Paracetamol leverages taste and GI mildness to dominate via non-tablet preparations
-

# The Solution



- Platform technology with range of benefits providing for rich source of differentiation:
  - GI friendly delivering major reduction in GI mucosal damage
  - Significantly taste masks the bitterness and burn of NSAIDs
  - Delivers an attractive PK profile with tuneable drug release properties
- Multiple product applications for competitive advantage in both OTC, OTx and Rx markets
- IP from Oxford University, University of Queensland and in-house
- Scalable and cost effective manufacturing

# Competitive Advantage and Growth Pipeline

## Growth opportunities for major global brands

### Immediate

- leveraging taste masking/formulation

### Medium term

- leveraging adaptable PK properties

### Longer term

- opportunities leveraging GI claims



# Outlook & Summary

- Commercialisation process started for OXPzero™ Ibuprofen and OXPzero™ Naproxen
  - External transaction advisors engaged
  - Significant traction from key players
  - Simplified regulatory pathway confirmed by MHRA
- Pipeline progressing, focused on Aspirin and statins with further progress expected to be made in 2016.
- Strong balance sheet has put us in good position to negotiate from strength and advance our pipeline



# Appendix

---



- Management
- Case Study
- Financials
- Pipeline

# Management Team



Management	Selected Company Experience	Relevant Experience
<b>Marcelo Bravo</b> CEO, Founder	  	20 years
<b>Chris Hill</b> CFO	 Grant Thornton 	10 years
<b>Liz King</b> Director of R&D	   	18 years
<b>Sheryl Caswell</b> Clinical Development	 	19 years
<b>Ann Taylor-Hutchinson</b> Pharmaceutical Sciences	   	28 years

# Financial Highlights



## Statement of Comprehensive Income


	Year to 31 December 2015 £'000	Year to 31 December 2014 £'000
<b>Revenues</b>	749	705
Cost of sales	(591)	(482)
<b>Gross Profit</b>	158	223
Administrative expenses	(4,131)	(3,719)
<b>Operating loss</b>	(3,973)	(3,496)
Finance income	96	32
<b>Loss before tax</b>	(3,877)	(3,464)
Taxation	763	600
<b>Loss after tax attributable to equity holders of the parent</b>	(3,114)	(2,864)
<b>Loss per share</b>		
Basic on loss for the period (pence)	(0.28)	(0.29)
Diluted on loss for the period (pence)	(0.28)	(0.29)

- Operating loss for 2015 of £3.97m (2014: £3.50m) reflecting planned increase in R&D spend
- Cash and short-term deposits at 31 December 2015 of £23.1m (31 December 2014: £6.7m)


# Case Study: OXPzero™ Ibuprofen

## Reduced Incidence of Severe GI Mucosal Damage


(Lanza  $\geq 3$ , subjects with  $> 10$  erosions and / or ulcers)



## OXP001-003 Clinical Results – Taste Assessment<sup>(1)</sup>



## OXP001-003 Day 7 PK<sup>(2)</sup>




▪ **GI Damage:** 5.9 to 2.2 times odds of having Lanza  $\geq 3$  in Brufen than in OXPibuprofen™ group

▪ **Taste:** Clear ability of OXPzero to mask taste with Ibuprofen-LDH salt

▪ **PK:** Stays above 10  $\mu\text{g/ml}$  for approximately 1.5 hours longer than Brufen

(1) Response due to LDH technology since chewable tablet did not contain any sweeteners or flavouring.  
(2) 10  $\mu\text{g/ml}$  limit for onset of analgesia - K. Rainsford. Pharmacology, Therapeutics and Side Effects, 2012.

# Pipeline





## Contacts

Marcelo Bravo – CEO

Chris Hill – CFO

2 Royal College Street, London, NW1 0NH

[www.oxfordpharmscience.com](http://www.oxfordpharmscience.com).